<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03533478</url>
  </required_header>
  <id_info>
    <org_study_id>ALZER-DIAMEL-EMD-2014</org_study_id>
    <nct_id>NCT03533478</nct_id>
  </id_info>
  <brief_title>Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema</brief_title>
  <official_title>Efficacy of Nutritional Supplements Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema. Clinical Trial Phase II.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular edema is the main cause of low vision in diabetics. They continue looking for new
      treatment alternatives. The nutritional supplement Alzer, is a powerful antioxidant that
      together with Diamel, a supplement that has shown efficacy in metabolic control, could be a
      therapeutic option. Objective: To evaluate the therapeutic efficacy of the Alzer Diamel
      combination in mild and moderate macular edema. Material and method: A randomized
      double-blind phase II clinical trial versus placebo will be conducted in 64 patients, who
      will be randomly assigned to two groups, one will receive Alzer + Diamel and another will
      receive placebo from Alzer and Diamel. All patients will undergo clinical, biochemical and
      ophthalmological evaluation during the study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular retinal thickness</measure>
    <time_frame>1 year</time_frame>
    <description>macular retinal measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>visual acuity test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 patients with mild or moderate diabetic macular edema.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32 patients with mild or moderate diabetic macular edema</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral treatment Alzer y Diamel</intervention_name>
    <description>Alzer:
Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.
Diamel:
Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year.</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetics type 2 insulin treated.

          -  Age between 18 and 65 years.

          -  Glycosylated hemoglobin (HB A1c) &lt;8% at the beginning of the investigation.

          -  Patients who express written voluntariness to enter the study with their signature of
             the informed consent document.

          -  If woman of childbearing age, negative pregnancy test and use of barrier
             contraceptives.

        Exclusion Criteria:

          -  Pregnancy and lactation.

          -  Age over 65 years.

          -  Macular edema with vitreous-retinal traction or other cause (renal, arterial
             hypertension, post-surgical).

          -  Opacity of the refractive media that hinders the ophthalmological examination.

          -  History of hypersensitivity to another similar product or one of its components.

          -  Patients at potential risk of not compliance the study (those who will travel during
             the period of the investigation or distance in their residence, outside the city).

          -  Subjects who are participating in another clinical trial Patients with cognitive
             disorders or a mental disorder that hinders their follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juana Elvira Maciques Rodríguez, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Endocrinology, Cuba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Endocrinology</name>
      <address>
        <city>Vedado</city>
        <state>Havana</state>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nutritional supplement</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Alzer</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Diamel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

